| Document |
Document Title |
|
JP6585139B2 |
The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulati...
|
|
JP2019526601A |
A composition composed of a delivery vehicle or delivery system and an active agent dispersed in the delivery vehicle or delivery system, wherein the delivery vehicle or delivery system contains a polyorthoester polymer and a polar aprot...
|
|
JP6578277B2 |
Described herein are neuroactive steroids of the Formula (I):or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. T...
|
|
JP6574228B2 |
The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a local anesthetic in the form of a clear oily solution and methods for making same. The formulations can be administered by infiltration ...
|
|
JP6573968B2 |
This invention relates to novel Thieno- and Furo[2,3-d]pyrimidine-2,4[1H,3H]-dione derivatives of formula I and their use as TRPC5 modulators, pharmaceutical compositions containing the same, and methods of using the same as agents for t...
|
|
JP6570015B2 |
Pharmaceutical compositions and methods are described, the compositions comprising a benzodiazepine-based compound, a NMDA antagonist, a β-blocker and antiemetic. Methods for fabricating the compositions and using them for anesthesiolog...
|
|
JP2019142972A |
To provide pharmaceutical formulations suitable for parenteral administration of tapentadol and free of preservative-based side effects, such as allergic reactions.The invention provides an aqueous pharmaceutical composition adapted for ...
|
|
JP6568519B2 |
The present invention relates to a medical dressing that has a modular structure consisting of at least two layers and that is able to cleave incorporated photolabile nitric oxide donors in an adjoining absorption module by means of the ...
|
|
JP2019523212A |
Fast-acting oral disintegration for administration of local anesthetics to reduce physical and psychological discomfort in the oral cavity during procedures such as dental procedures, or generally to relieve pain such as toothache Film (...
|
|
JP2019135261A |
To provide (3α,3β)-disubstituted 17β steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof for prevention and treatment of a variety of CNS-related conditions.In another aspect, provid...
|
|
JP2019131586A |
To provide, generally, hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.A hydrogel composition comprises a crosslinked hyaluronan based polymer and at least one additional agents sele...
|
|
JP6556154B2 |
The Invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, or diastereomers thereof: wherein W1, W2, W3, J1, J2, A, R1, R2, R3, R4, R5, a, and b are defined as set forth in the sp...
|
|
JP2019123730A |
To provide methods for providing pain relief and anesthesia in human subjects.Disclosed herein is a method for administering to a human subject R-dihydroetorphine. Also disclosed is a method for providing pain relief in a subject in whic...
|
|
JP2019116478A |
To provide devices for preparing limit size lipid nanoparticles with a diameter from 10 to 100 nm.Provided is a device for producing limit size lipid nanoparticles, comprising: a first inlet for receiving a first solution comprising a fi...
|
|
JP6545490B2 |
The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof.
|
|
JP6543625B2 |
The present invention relates to an injection device suitable for intraepidermal and/or intradermally and/or subcutaneously comprising a sterile and injectable composition, said composition being prepared by a method comprising at least ...
|
|
JP6542127B2 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...
|
|
JP6539671B2 |
A method for producing a flurane complex, comprising the steps of producing an aqueous solution of sulfobutylether-β-cyclodextrin (SBECD); controlling the temperature of said solution to a temperature of from 2 to 15° C.; adding the fl...
|
|
JP2019518040A |
DNA-targeted nanocarriers are provided for encapsulating the active agent and for delivering the active agent to extracellular DNA. Their nanocarriers, such as polymer particles, liposomes and multilayer vesicles, have DNA-targeting moie...
|
|
JP2019516773A |
Hereinafter, compounds for regulating transient receptor potential vanilloid 1 receptor (TRPV1) activity, pharmaceutical compositions and pharmaceuticals containing such compounds, and methods of using such compounds are described. be wr...
|
|
JP6529917B2 |
A system and process for the recovery of at least one halogenated hydrocarbon from a gas stream. The recovery includes adsorption by exposing the gas stream to an adsorbent with a lattice structure having pore diameters with an average p...
|
|
JP2019514446A |
An anesthetic halocarbon capture system is provided. The system can insert a pressure intolerant sleeve containing a filter material that captures one or more types of anesthetic halocarbons prior to supercritical fluid extraction, and t...
|
|
JP2019514983A |
The present invention relates to a method of treating a particular activated skin disorder in a subject, comprising administering to the subject an effective amount of an agent capable of reducing energy metabolism. Agents that reduce en...
|
|
JP2019513799A |
Compositions for transdermal delivery of active ingredients and usage of such compositions are disclosed herein. [Selection diagram] None
|
|
JP2019513796A |
The present invention relates to an oral inhalation and nasal preparation (OINDP) containing a benzodiazepine, in particular remimazolam.
|
|
JP6514718B2 |
The present invention relates to a device for the topical treatment of pain affecting the vulvar area of the female human genital organ, a formulation for use in the device according to the invention, and a kit comprising the device acco...
|
|
JP6502350B2 |
A method of providing anesthesia and organ-protection to a subject in need thereof comprises co-administering to the subject a non-anesthetic protective gas in an amount effect to provide organ protection, and a liquid anesthetic agent i...
|
|
JP6502480B2 |
The present invention relates to a pharmaceutical preparation of a compound of formula (I) or stereoisomer, pharmaceutically acceptable salt, prodrug thereof, and a novel method for general anesthesia or sedative for mammals. Also provid...
|
|
JP6499192B2 |
A sprayable emulsion is provided. The emulsion can be used in the treatment of various skin conditions. The emulsion includes a hydrofluoro-based propellant, an emulsification system, an oil phase, a water phase, and active agent particl...
|
|
JP2019508505A |
The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compound of the present invention can be represented by the formula (I).
|
|
JP2019508472A |
The present invention provides compositions and methods for the treatment of presbyopia and other visual defects. The composition preferably contains acetylidine and a polyol and / or a ciliary muscle numbing agent. The composition optio...
|
|
JP2019043945A |
To provide a composition for external use which is an emulsion and suppresses separation between a water phase and an oil phase.There is provided a composition for external use which comprises an antihistaminic agent and a vegetable oil ...
|
|
JP6486563B2 |
b) 0.1-15 wt % of at least one surfactant (B) and c) 1-30 wt % of water, wherein A is a hydrophilic block having a number average molecular weight (Mn) of 100-1,000 Da, B is a hydrophobic block made from monomers having at least a monome...
|
|
JP2019506397A |
A method of relieving pain caused by metatarsal neuroma in a patient for a period of at least 3 months, at least first to relieve pain caused by metatarsal neuroma. A dose of capsaicin, and a second dose of capsaicin after 1 month of the...
|
|
JP2019506435A |
Treating patients with one or more doses of HPV recombinant vaccine for cancer, benign tumors, or lesions associated with HPV, including skin cancer and especially squamous cell carcinoma (SCC) and basal cell carcinoma. Or a way to reduc...
|
|
JP2019031531A |
To provide azaspiro[4.5]decane derivatives, and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof.There is provided use of pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and dias...
|
|
JP6461210B2 |
The invention concerns a cartridge for an inhalation device for delivering anaesthetic to a human or animal wherein anaesthetic in said cartridge is dispersed in an anaesthetic control release medium; an inhalation device for use with sa...
|
|
JP2019501221A |
The present invention belongs to the field of pharmaceutics and relates to topical formulations for the treatment of extracellular matrix components of peripheral joints, spinal joints and / or connective tissue. The formulations of the ...
|
|
JP2019001824A |
To provide polyorthoester and a composition of aprotic solvent.A delivery system and a composition contain biodegradable polyorthoester polymer, aprotic solvent, and drug. Solvent is selected so as to adjust drug release from the composi...
|
|
JP2019000090A |
To provide a management method capable of reducing a toxic component in a water tank in order to prevent sudden death of fish and shellfish.In a water tank storing fish and shellfish in the anesthetic state, a carbon dioxide concentratio...
|
|
JP2018537417A |
The present invention relates to a benzodiazepine derivative of formula I as a short-acting anesthetic, a pharmaceutical composition containing it, a kit containing it, a method for preparing the same, an anesthetic method using the same...
|
|
JP2018536709A |
Treatment of various diseases, including ear anesthesia of various cranial nerves. The pharmaceutical composition is administered to the ear canal of the subject in need of such treatment, the composition comprising an analgesic and / or...
|
|
JP6437636B2 |
The present invention provides amphiphilic compounds with a tetradecahydrophenanthrene skeleton of formula (I), wherein R1-R5 are as defined herein, and their enantiomers, exhibiting neuroprotective effects, for use as medicaments for tr...
|
|
JP6437112B2 |
The present invention relates to compositions and methods for treating fat deposit accumulation in a subject. The invention provides a non-surgical method for reducing fat deposits comprising administering an effective amount of a fat-ly...
|
|
JP6431155B2 |
The present invention relates to a phenol derivative and the preparation method and use in medicine thereof, and particular to a phenol derivative represented by general formula (A) or a stereoisomer, a solvate, a metabolite, a prodrug, ...
|
|
JP2018533629A |
Hydrocinnamate compounds that exhibit proteasome regulatory activity, especially proteasome inhibitory activity, can be used to treat eye disorders associated with proteasome activity locally or systemically. Hydrocinnamate compounds can...
|
|
JP6422498B2 |
The invention provides azaspiro[4.5]decane derivatives of Formula (A): and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, and diastereomers thereof, wherein A1, X, A2, Rr, R2′, W1, W2, R3′, R4′, a, and b are defin...
|
|
JP2018168069A |
To provide novel analgesics and/or analgesic adjuvants.The analgesic of the present invention comprises an interleukin-31 agonist (IL-31 agonist) as an effective ingredient. The present invention also provides a pharmaceutical compositio...
|
|
JP2018531951A |
Described herein are sustained release formulations of polymer-coated local anesthetics and their use for relieving or managing pain, including postoperative pain. [Selection diagram] Fig. 6
|
|
JP2018531065A |
The multi-chamber syringe unit (10) has a side wall (210), a distal end (230), a proximal end (220) opposite the distal end (230), and a distal end (220). An interior defined by a side wall (210) between the 230) and the proximal end sid...
|
